Procept BioRobotics reports Q4 EPS (54c), consensus (44c)

Reports Q4 revenue $43.58M, consensus $42.06M. “I am extremely proud of our commercial achievements in 2023,” said Reza Zadno, CEO. “We succeeded in elevating the average monthly utilization in the U.S. by approximately 10%-an exceptional achievement, especially considering the significant 89% increase in our install base. As we enter 2024, we believe there are several positive factors that will enable us to continue to pursue our long-term growth strategy while also demonstrating a disciplined approach on our path to profitability. We believe these underlying fundamentals reflect a technology that is establishing the foundation to become the BPH surgical standard of care and a business poised to be a leading Urology company globally.”